Canada: Health Canada Releases Guide To Implementing The Protecting Canadians From Unsafe Drugs Act (Vanessa's Law)

Health Canada has issued a draft Guide as a companion to last year's amendments to the Food and Drugs Act made pursuant to Bill C-17 - Protecting Canadians from Unsafe Drugs Act (Vanessa's Law). The amendments granted Health Canada the regulatory authority to collect data about a "therapeutic product" (defined in the Act as a drug or a medical device, excluding natural health products) prior to, or following market entry, and to take swift action to protect the health of the public when the Ministry identifies a risk.

Certain statutory powers enacted by Vanessa's Law came into force upon royal assent, including the Minister's ability to:

  • require a person to provide information;
  • disclose confidential business information;
  • order a label change or package modification;
  • order a recall; and
  • seek an injunction in response to offences or suspected offences under the Act.

However, as discussed in a previous blog post, much of the mechanics for implementing the Vanessa's Law amendments will be developed through the regulations. Similarly, the remaining statutory powers, including the power to order an assessment of a therapeutic product, and the power to require health care institutions to disclose information about "serious adverse reactions" to a therapeutic product, will not come into force until the passage of the underlying regulations.

The draft Guide, which is subject to public comment until June 8, 2015, was developed to ensure that Health Canada applies these new authorities (and in particular, the statutory powers that are now in force) in a manner that is fair and consistent and to facilitate the creation of operational procedures within Health Canada's Health Products and Food Branch. In addition, although not a stated objective of the Guide, the information in the Guide will also assist manufacturers, therapeutic product authorization holders and others in preparing internal policies and procedures for complying with the amended legislative and regulatory framework.

Guiding Principles

The Guide establishes a set of principles, policies and standards to follow when the Minister of Health and/or Health Canada exercises these new powers under the Food and Drugs Act. Although not legally binding, guidance documents "assist industry and health care professionals on how to comply with the policies and governing statutes and regulations ... [and] also serve to provide review and compliance guidance to staff, thereby ensuring that mandates are implemented in a fair, consistent and effective manner." Moreover, a marked departure by the Minister from the Guide could arguably be used to demonstrate the "unreasonableness" of a Minister's decision/actions in the context of a subsequent judicial review.

The underlying principles animating the Guide stress that the Minister should exercise powers of decision in a reasonable, unbiased and transparent manner that is grounded in scientific evidence.

The Guide also provides valuable information on who can use the powers described in the legislation, to what/whom these powers apply, the thresholds that must be satisfied before the Minister can exercise a statutory power, and the scope of the power.

Risk Analysis

Notably, the amendments to the Food and Drugs Act did not include a definition as to what constitutes a "serious risk", which is the threshold to be satisfied before the Minister can exercise her powers to require the disclosure of confidential business information, or to issue a recall pursuant to the legislative scheme. While it is likely that a definition will be provided for in the forthcoming regulations, the Guide does offer a non-exhaustive list of criteria for the Minister to consider when assessing whether a product poses "serious risk", including:

  • The seriousness of the adverse health consequences (such as death, life-threatening injury, hospitalization, disability/incapacity, or birth defects), including the frequency of serious adverse health consequences, and the probability of the occurrence of a serious adverse health consequence.
  • The vulnerability of the affected population. For example, children, the elderly, pregnant women, or patients whose immune systems are comprised are often categorized as vulnerable populations.
  • The number of people potentially affected by the product.

Applying the Law

The Guide provides that when exercising a statutory decision-making power under the Food and Drugs Act, the Minister should observe a number of principles, including but not limited to the following:

  • In most cases, notifications should precede an order to facilitate companies taking voluntary steps to resolve issues. Notifications should set out the facts relied upon to form the basis of the Minister's opinion, and should provide the affected person with an opportunity to respond, which gives affected entities the opportunity to correct factual inaccuracies, dispute the case against him, or to voluntarily comply with the notification. The time frame for a response will be dictated by the severity and immediacy of the risk.
  • A determination regarding whether the elements of the statute have been met will come in the form of a recommendation from Health Canada after consideration of the scientific evidence.
  • The Minister must disclose and provide reasons explaining the scientific evidence to support her decision-making, so that the affected party understands why and how the decision was reached. For example, the Guide prescribes that the following information should be disclosed:
    • a narrative and chronological review of the facts;
    • the scientific evidence considered;
    • findings regarding important questions of fact and the accompanying analysis;
    • relevant criteria considered as part of the threshold determination of whether to exercise the Minister's statutory power; and
    • an explanation of how the evidence satisfies the threshold.
  • In the interests of transparency, orders must be made publicly available.
  • 48 hours' notice will be given to persons named by Health Canada in injunction applications, unless there are exigent circumstances such that notice would not be in the public interest.
  • The power to compel information is limited to existing information, and cannot be used to order a person to create new information (i.e. new studies).
  • Confidential business information that may be disclosed pursuant to the Food and Drugs Act to prevent a serious risk of injury to human health should only be disclosed to the extent necessary to mitigate the serious risk of injury to human health. Note that the provisions regarding what constitutes confidential business information will be subject to supporting regulations developed at a later date.
  • Confidential business information that may be disclosed to governments, persons from whom the Minister seeks advice or a person who is engaged with the protection or promotion of human health or the safety of the public can be used to protect patients from safety risks or promote the safe use of therapeutic products.
  • Disclosures of confidential business information must be compliant with Canada's international treaty obligations under TRIPS and NAFTA.
  • The regulations regarding voluntary recalls are still operative, however a mandatory recall Order should be issued when a seller is not willing to recall a therapeutic product that is believed to present a serious or imminent risk of injury to health.
  • In certain circumstances, products subject to a recall may continue to be sold with or without conditions, such as in a situation where the withdrawal of the product would present a greater risk to health than the risk of not recalling the product.

What's Next?

Notwithstanding the fact that it may be some time before the underlying regulations are released, many of the statutory powers contemplated by the amendments introduced by Vanessa's Law are now in force. The Guide provides some much-needed clarity on how Health Canada will apply these new authorities.

In the interim, two key measures have been implemented in furtherance of Health Canada's Regulatory Transparency and Openness Framework, which seeks to facilitate the ability of the average Canadian to make "well-informed decisions concerning their health and that of their families". On March 23, 2015, Health Canada launched an initiative seeking feedback from stakeholders in the healthcare industry to assess their information needs about therapeutic products. Stakeholders are invited to participate in an online survey containing questions about how information is used, for what purpose, and how to improve the dissemination of information. The results of this consultation, which remains open until May 25, 2015, will likely influence the regulations being developed under Vanessa's Law.

On April 13, 2015, Health Minister Rona Ambrose also launched the online Drug and Health Product Inspections Database, which allows all visitors to search for historical information on inspections of companies who manufacture and sell drugs for consumption in Canada. Currently, the site allows users to search for the results of inspections conducted from 2012 onwards, whether the company is currently licensed, and whether there are any terms under which the company must operate.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions